Eli Lilly: Credit Suisse downgrades stock

(CercleFinance.com) - Credit Suisse has downgraded its rating on the Eli Lilly stock from "neutral" to "underperform" and has cut its corresponding target price from 88 dollars to 82 dollars, underlining the challenges that face the pharmaceutical group in diabetes.


Analysts remind us that they downgraded their rating on the stock to "neutral" in October 2017, having been worried about the increasing competitive challenges against diabetes - Trulicity and Humalog - with the stock having fallen by 2% since then (against +10% for the S&P).

Credit Suisse says that it is " increasingly uncomfortable with the outlook for these products and others," and it does "not believe LLY is on track to hit their mid-term guidance of 5% sales CAGR from 2015-2020".


Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.